ROIV
Roivant Sciences Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$38.88
+6.17%0
Insider buys (3m)
21
Insider sells (3m)
-$74.4M
Net value (3m)
+5.2%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Nov 5, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 200,000 | $36 |
| Oct 30, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 200,000 | $37 |
| Oct 27, 2026 | MOMTAZEE JAMES C · director | F-InKind | 77 | $36 |
| Oct 27, 2026 | Oren Ilan · director | A-Award | 810 | $0.00 |
| Oct 27, 2026 | Epperly Melissa B, · director | F-InKind | 116 | $36 |
| Oct 27, 2026 | MOMTAZEE JAMES C · director | A-Award | 383 | $0.00 |
| Oct 27, 2026 | Epperly Melissa B, · director | A-Award | 513 | $0.00 |
| Oct 22, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 14,144 | $35 |
| Oct 22, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 185,856 | $35 |
| Oct 20, 2026 | Sukhatme Mayukh · director, officer: President & CIO | F-InKind | 19,976 | $34 |
| Oct 20, 2026 | Gline Matthew · director, officer: CEO | F-InKind | 34,638 | $34 |
| Oct 5, 2026 | Epperly Melissa B, · director | Sale | 900 | $37 |
| Oct 5, 2026 | Epperly Melissa B, · director | M-Exempt | 17,750 | $4.46 |
| Oct 5, 2026 | Epperly Melissa B, · director | Sale | 16,850 | $36 |
| Oct 2, 2026 | Torti Frank · officer: President and Vant Chair | F-InKind | 40,309 | $37 |
| Oct 2, 2026 | Venker Eric · officer: President & Immunovant CEO | M-Exempt | 200,000 | $3.85 |
| Oct 2, 2026 | Venker Eric · officer: President & Immunovant CEO | Sale | 200,000 | $37 |
| Oct 2, 2026 | Sukhatme Mayukh · director, officer: President & CIO | F-InKind | 46,879 | $37 |
| Oct 2, 2026 | Gline Matthew · director, officer: CEO | F-InKind | 76,171 | $37 |
| Sep 22, 2026 | Pulik Richard · officer: CFO | F-InKind | 2,129 | $40 |
| Sep 22, 2026 | Humes Jennifer · officer: Chief Accounting Officer | F-InKind | 3,880 | $40 |
| Sep 18, 2026 | MANCHESTER KEITH S · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Gold Daniel Allen · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | MANCHESTER KEITH S · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Gold Daniel Allen · director | A-Award | 10,531 | $40 |
| Sep 18, 2026 | Fitzgerald Meghan · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Epperly Melissa B, · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Oren Ilan · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | MOMTAZEE JAMES C · director | A-Award | 5,054 | $0.00 |
| Sep 18, 2026 | Oren Ilan · director | A-Award | 10,531 | $40 |
Institutional positioning
13F filings over the trailing two quarters
New 210Increased 417Reduced 269Sold out 60
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 81,020,390 | Aug 13, 2026 |
| FMR LLC | Increased | 77,981,253 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 51,828,325 | May 15, 2026 |
| FMR LLC | Increased | 51,666,511 | Nov 5, 2026 |
| FMR LLC | Increased | 49,301,583 | Nov 5, 2026 |
| FMR LLC | Increased | 49,145,056 | Nov 5, 2026 |
| BlackRock, Inc. | Increased | 48,236,091 | Aug 7, 2026 |
| FMR LLC | Increased | 46,551,146 | Nov 5, 2026 |
| BLACKROCK, INC. | Increased | 44,254,260 | May 13, 2026 |
| MORGAN STANLEY | Reduced | 42,592,905 | Aug 13, 2026 |
| FMR LLC | Increased | 38,910,625 | Nov 5, 2026 |
| FMR LLC | Reduced | 36,976,248 | Nov 5, 2026 |
| FMR LLC | Increased | 35,997,134 | Nov 5, 2026 |
| FMR LLC | Reduced | 35,340,563 | Nov 5, 2026 |
| FMR LLC | Increased | 30,762,284 | Nov 5, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Nov 5, 2026